Navigation Links
Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees
Date:5/2/2008

NUTLEY, N.J., May 2 /PRNewswire/ -- Two Roche employees were recognized for their significant contributions to industry in New Jersey at the 34th Annual TWIN Awards Dinner held May 1, 2008. Honored were Jennifer Dudinak, Pharm.D., group director, Oncology, Drug Regulatory Affairs, and Sherrie Pietranico-Cole, Ph.D., research leader, Discovery Chemistry.

"These individuals exemplify the best and brightest at Roche. They have made outstanding contributions to the company's success, and to the health care industry as a whole," said George Abercrombie, president and CEO of Hoffmann-La Roche Inc., adding that the 2008 awardees join the 79 Roche pharmaceutical employees recognized since TWIN began 34 years ago.

TWIN, which stands for Tribute to Women and INdustry, is sponsored by the YWCA of Bergen County to recognize women who have achieved responsible managerial, executive or professional positions and have made noteworthy contributions to their industries.

The Awardees

Jennifer Dudinak, Pharm.D., is group director of Oncology in Drug Regulatory Affairs, which is the key interface between Roche and health authorities, such as the U.S. Food and Drug Administration (FDA). She leads a team responsible for overseeing the regulatory approval process for promising new cancer drugs or new indication on existing drugs that have completed the clinical trial phase. She also was recently appointed as the Pharmaceutical Development Regulatory (PDR) Partner to the company's Oncology Disease Biology Area team.

"Other TWIN winners have been tremendous role models for me, so to receive this award is very humbling," she said.

Dr. Dudinak joined Roche in 1997 as part of the Roche/Rutgers Post-Doctoral Fellowship Program and in 1999 became part of the PDR management team. She has worked in all phases of drug development leading several investigational new drug and global dossiers for new and supplemental indications. She also served as Interim Head of U.S. Operations in Drug Safety for part of 2007. Before Roche, she worked in several clinical practice settings including retail, hospital and community pharmacy. She received a Doctorate of Pharmacy and Bachelors of Pharmacy from Rutgers University.

In addition to her work with Roche, Dr. Dudinak promotes women's wellness education in New Jersey through community outreach organizations. She and her husband, Michael, have a son, Justin 2, and are expecting their second child in June.

"Jennifer provides strong leadership, keen strategic vision and outstanding communication and teamwork skills. She has a positive track record of inspiring and motivating all who have had the opportunity to work with her," said Cindy Dinella, Pharm.D., vice president, Drug Regulatory Affairs.

Sherrie Pietranico-Cole, Ph.D., is research leader, Discovery Chemistry. She is currently involved in the design and discovery of new drugs for the treatment of diabetes and metabolic syndrome and has led teams that, in the past two years alone, have brought two promising compounds to the point of human studies.

"I feel very fortunate that I am able to work on discovering medicines that help people and make this world a better place. The TWIN award is a tremendous honor, especially since I have admired many past Roche recipients," she said.

Dr. Pietranico-Cole joined Roche in 1992, after graduating from the University of Pennsylvania with a Ph.D. in chemistry -- the first woman of African American descent to do so. Work she did there with two renowned chemistry professors was published in the Journal of the American Chemical Society and is still regarded as groundbreaking progress in the field of peptide mimetics. She earned her B.S. degree in chemistry from Rutgers University-Douglass College.

In addition to her work with Roche, Dr. Pietranico-Cole is deeply committed to promoting science education and mentoring disadvantaged children. She spends much time volunteering in schools, local museums and with the Roche Student Enrichment Program. She and her husband, Dr. Brian Cole, have two children, Jasmine, 12, and Brian Jr., 9.

"Sherrie has tremendous scientific talent and leadership skills, and is not only a role model at Roche, but also for the hundreds of children she inspires in her professional outreach," said Jefferson Tilley, Ph.D., senior research director, Discovery Chemistry.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune). For additional information about the U.S. pharmaceuticals business, visit our website: http://www.rocheusa.com. Product and treatment information for U.S. healthcare professionals is available at http://www.RocheExchange.com.

All trademarks used or mentioned in this release are protected by law.

Contact(s): Public Affairs

(973) 235-2699


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Research Director Grace Ju Hailed as NJABR Outstanding Woman of Science
2. MacroChem Acquires Virium Pharmaceuticals
3. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
4. Roche Molecular Diagnostics Invests $57.5 Million in Green Research Building
5. MacroChem Appoints David P. Luci as New CFO
6. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
7. Roche to Acquire Ventana for $89.50 per share
8. Roche Extends Tender Offer for Ventana
9. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
10. Roche Files IND for Second Genmab Antibody
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):